10-Q · May 13, 2026
Sunshine Biopharma's Q4 2026 10-Q reflects a decline in both revenue and profitability metrics, continuing the trend from previous quarters. The company reported a revenue of $8.09 million, down 9.1% year-over-year,…
Earnings analysis · 10-Q
SBFM earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text is limited to the latter sections of the filing and does not provide current-quarter financial statements, segment results, MD&A, cash-flow data, or quantitative guidance. Management reported…
Read full summary
The supplied 10-Q text is limited to the latter sections of the filing and does not provide current-quarter financial statements, segment results, MD&A, cash-flow data, or quantitative guidance. Management reported effective disclosure controls as of June 30, 2026 and no material control changes during the quarter. The company also reported no material legal proceedings, no unregistered securities sales, and no defaults upon senior securities, but the absence of financial and risk-factor detail prevents an assessment of operating momentum.
What stood out
-
Controls assessed effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, at reasonable assurance levels.
-
No material control changes
The company reported no changes in internal control over financial reporting during the quarter ended June 30, 2026, that materially affected or were reasonably likely to materially affect those controls.
-
No material legal proceedings
Sunshine Biopharma stated that it was not party to, and its property was not the subject of, any material legal proceedings as of the filing.
-
No reported equity sales or defaults
The company reported none for unregistered sales of equity securities and none for defaults upon senior securities during the reported period.
What to watch
-
Risk-factor disclosure unavailable
The company is a smaller reporting company and stated it is not required to provide Item 1A risk-factor disclosures; consequently, the supplied 10-Q does not provide a current-period update against the prior filing.
-
Operating data not available in extract
The provided filing extract does not include the Part I financial statements or MD&A, so current-quarter revenue, margins, EPS, cash flow, liquidity, and working-capital trends cannot be verified from the supplied text.
-
Market-risk disclosure limited
The filing states that the company is not required to provide quantitative and qualitative market-risk disclosures under Item 3 because it is a smaller reporting company.
Management's outlook
The provided 10-Q extract contains no quantitative revenue or EPS outlook. No operating guidance, liquidity outlook, or capital-spending outlook was disclosed in the supplied text.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.